In addition, and similar to studies in humans, the mTOR inhibitor rapamycin was capable to restore T cell metabolism and to decrease disease activity in lupus-prone MRL/lpr mice (92, 93). This evidence concerns the gene MTOR and systemic lupus erythematosus.